Glenmark Pharma posted stable quarter with a slowdown seen in their Indian business. In an interview to CNBC-TV18, Glenn Saldanha, CMD of Glenmark spoke about the results and his outlook for the company.

Cash from out-licensing GBR 830 will be used for repayment of debt: Glenmark

Glenmark Pharma has announced positive data from a phase 2a study of the molecule GBR 830, which was being studied for moderate-to-severe atopic dermatitis. In an interview to CNBC-TV18, Glenn Saldanha, CMD of the company spoke at length about the molecule.

Govt needs to be a strong enabler in pharma sector: Experts

Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.

New launches to drive earnings growth in FY18 & FY19: Glenmark

The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said.

Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

See EBITDA margins at 25% over 10 years: Glenmark CMD

The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.

Expect better performance from core US biz in Q3: Glenmark

Glenn Saldanha says Zetia Generic - a drug to keep a check on cholestrol levels - will be launched on December 12. The launch could see USD 200-250 million in revenues. The company is going to use the money from here to bring down company's debt.

New products, regulatory approvals to drive growth for Glenmark

The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing Director Glenn Saldanha.

Awaiting $45 million from Venezuelan govt: Glenmark Pharma

With the big product launch of Ezetimibe (a cholesterol-lowering drug), company's topline revenue to be over 25 percent, where 45 percent will be contributed by the US and 20-25 percent by the Indian business, says Glenn Saldanha, Chairman & MD of Glenmark Pharmaceuticals.

Aim is to prevent rampant use of antibiotics: P Lilladher

Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

See 18-20% growth, 10-12 product launches in US: Glenmark

According to CMD Glenn Saldanha, emerging markets will see positive growth for the company in FY16. The company continues to invest in emerging markets.

Sun's margins may reduce to 30-32% post merger: Surajit Pal

As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

India Q2 biz has outperformed; maintain guidance: Glenmark

Glenn Saldanha, chief executive officer, Glenmark says that while the US business has been a drag, India business has been an outperformer for the company.

GBR 1302 could be an out-licencing opportunity: Glenmark

GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.

Glenmark: Environment challenging, see 20% growth in FY14

Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.

Glenmark to get USD 9 mn upfront: CEO; stk at 52-wk high

Shares of Glenmark Pharmaceuticals rose over 2 percent to a 52-week high of Rs 512.65 on Monday morning following its agreement with Forest Laboratories on a collaboration for development of inhibitors to treat chronic inflammatory conditions, including pain.

May not see 35% growth in H1 sustaining in H2: Glenmark

Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead.

Launches in FY13 to boost growth in Indian market: Glenmark

Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.

Glenmark Pharma sees its India business growing at 23-24%

Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.

Glenmark confident of US growth despite Tarka issue

In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."